SUBSCRIBE
SUBSCRIBE

Faraday Pharmaceuticals

NEWS
Senior Female Scientist Works with High Tech Equipment in a Modern Laboratory. Her Colleagues are Working Beside Her.
Drug Development
Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio’s pediatric methylmalonic acidemia study is back up and running and another look at Roche’s TIGIT flop.
May 13, 2022
 · 
7 min read
 · 
Mark Terry
BioForest
Clinical Catch-Up: October 11-15
It was yet another busy week for clinical trial announcements. Take a look.
October 15, 2021
 · 
11 min read
 · 
Mark Terry
IN THE PRESS
Press Releases
Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury
April 25, 2025
 · 
5 min read
Press Releases
Faraday Pharmaceuticals to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
February 5, 2025
 · 
1 min read
Press Releases
Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference
November 6, 2024
 · 
1 min read
Drug Development
Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent
January 4, 2024
 · 
4 min read
Drug Development
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial InfarctionIocyte AMI-3 Trial
May 10, 2022
 · 
4 min read
Drug Development
Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart AttackTo be Published in the International Journal of Cardiology
December 27, 2021
 · 
3 min read
Drug Development
Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness
October 14, 2021
 · 
2 min read
Drug Development
Faraday Pharmaceuticals Announces Positive Top-Line Results from Phase 2 Trial of FDY-5301 for Treatment of Reperfusion Injury Following a STEMI Heart Attack
November 19, 2019
 · 
3 min read
Drug Development
Faraday Pharmaceuticals Announces Presentation of Clinical Data from Phase 2 Trial of FDY-5301 at the American Heart Association Scientific Sessions 2019
November 12, 2019
 · 
1 min read
Drug Development
Faraday Pharma Announces First-In-Human Trial Of FDY-5301
September 23, 2016
 · 
1 min read
JOBS